Harvard Heart Letter

Trial fails to enhance cholesterol drug's reputation

Research found that the cholesterol drug Vytorin, which combines Zetia with the statin Zocor, is no more effective than a statin alone at preventing plaque from growing in arteries.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In